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ABSTRACT 
Mycobacterium tuberculosis, the cause of Tuberculosis (TB), infects one third 
of the world’s population and causes substantial mortality worldwide. In its 
shortest format, treatment of drug sensitive TB requires six months of multidrug 
therapy with a mixture of broad spectrum and mycobacterial specific antibiotics, 
and treatment of multidrug resistant TB is much longer. The widespread use of 
this regimen worldwide makes this one the largest exposures of humans to 
antimicrobials, yet the effects of antimycobacterial agents on intestinal 
microbiome composition and long term stability are unknown. We compared the 
microbiome composition, assessed by both 16S rDNA and metagenomic DNA 
sequencing, of Haitian TB cases during antimycobacterial treatment and 
following cure by 6 months of TB therapy. TB treatment does not perturb overall 
diversity, but nonetheless dramatically depletes multiple immunologically 
significant commensal bacteria. The perturbation by TB therapy lasts at least 
1.5 years after completion of treatment, indicating that the effects of TB 
treatment are long lasting and perhaps permanent. These results demonstrate 
that TB treatment has dramatic and durable effects on the intestinal microbiome 
and highlight unexpected extreme consequences of treatment for the world’s 
most common infection on human ecology.  
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CHAPTER ONE - INTRODUCTION 
Introduction to Tuberculosis disease 
Each year, 3 – 4% of all deaths worldwide from any cause are attributable to 
infection with Mycobacterium tuberculosis (Mtb), the causative agent of 
Tuberculosis (TB) disease, which amounts to almost 5,000 TB-related deaths 
each day (1). This colossal disease burden necessitates a thorough 
understanding of both the pathogenic strategies Mtb uses to cause disease, 
as well as the host susceptibilities Mtb has evolved to exploit. Individuals can 
be uninfected, infected with latent Mtb, have active TB disease, or be cured 
through antibiotic therapy (Figure 1).  
 
Many factors can influence the probability that some individuals transition from 
one of these stages to another, but most defined risk factors compromise 
immune function (2). For example, untreated HIV infection, which depletes 
CD4+ T cells, is associated with elevated risk of TB disease. Overall, immune 
status is also affected by age—the elderly and young infants are at a 
disproportionately high risk of Mtb infection and subsequent TB disease. 
Furthermore, genetic mutations in pathways involved in controlling Mtb 
infection and maintaining latency, like those of IFNg and TNFa, also cause an 
increased risk of active TB disease (3). Despite these examples, known 
immune deficiencies are not sufficient to explain why the incidence of new 
active TB cases hovers over 10 million people each year, with a mortality rate 
between 1.5 – 2 million people (1). Furthermore, it is unknown why some 
individuals in TB endemic countries (where Mtb exposure is common) never 
become Mtb infected, why most latently infected individuals never progress to 
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active TB disease, and what may account for treatment failure, relapse, and 
re-infection. These epidemiological curiosities drive the questions proposed in 
this thesis.  
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Figure 1: The stages of Mtb infection and TB disease. Individuals in TB endemic countries are 
exposed to Mtb at home or in the community throughout their lifetimes. Some individuals, 
despite this exposure, remain IGRA– while others develop latent TB disease (LTBI), and are 
IGRA+. Around 5 – 15% of individuals with LTBI will go on to have active TB disease, where 
they are able to infect others around them. Since TB is a curable disease, people can take 
treatment for a minimum of 6 months with four antibiotics (HRZE). Since the turn of the 
century, more than 50 million lives have been saved by antimycobacterial TB therapy.  
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Epidemiology of Tuberculosis 
Mtb has co-evolved with humans for centuries, to the point where the only 
known natural reservoir is in Homo sapiens. Innumerable factors describe why 
some individuals get this disease while others do not, and despite all we know 
about TB, there are some elusive epidemiological questions that remain 
unsolved. First, individuals—even those who are exposed to Mtb throughout 
their lives—can remain uninfected, measured as being negative for the 
IFNg release assay diagnostic test (IGRA–). Second, it is believed that nearly 
one third of the world’s population is latently infected with live Mtb bacteria 
(clinically called LTBI), and are therefore IGRA+. More than 80% of these 
people will never get sick with active TB disease. Third, of the people who do 
get sick with active TB disease, depending on the susceptibility of the Mtb 
strain they are infected with to a standard course of antimycobacterial therapy, 
individuals with active disease can take treatment, thus, TB is a curable 
disease. These stages are depicted in Figure 1. Being cured from TB is 
achieved through a standard course of TB treatment, which consists of four 
antibiotics for two months, followed by two antibiotics for at least an additional 
four months. This makes antimycobacterial therapy for TB disease a full six 
months—one of the longest courses of antibiotic treatment administered to 
humans for any infectious disease.  
 
It is unknown why nearly 20% of individuals in TB endemic countries remain 
IGRA– throughout their lifetimes, despite what is assumed to be persistent 
exposure. It is further unknown why 5 – 15% of individuals with LTBI will 
progress to active TB disease, whereas most people’s immune systems are 
able to keep Mtb at bay for their entire lives. Finally, we do not know why 
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individuals who have had TB and have been cured through antibiotic 
treatment are more than four times more likely to become re-infected with Mtb 
again in their lifetimes.  
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Figure 2 
Mechanism of action and 
chemical structures of 
HRZE drugs and their 
described active products. 
Isoniazid (H) is a prodrug, 
which requires the 
mycobacterial protein KatG 
(Rv1908c) for ligation with 
NAD+, the product of which is 
the active drug that inhibits 
enoyl-acyl carrier protein 
reductase InhA, inhibiting 
fatty acid biosynthesis. 
Pyrazinamide (Z) is activated 
by the mycobacterial enzyme 
PncA to pyrazinoic acid. 
Ethambutol (E) targets 
arabinogalactan biosynthesis, 
and Rifampicin (R) inhibits 
Mycobacterial DNA-
dependent RNA polymerase 
through binding to the β-
subunit of the enzyme.  
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Calculating what epidemiological factors contribute to LTBI and TB disease 
incidence is by no means trivial. The goal is to estimate the percent of total 
incidence of disease in the population due to a given epidemiological factor 
(exposure), and to have the numbers from all contributing factors to add up to 
100%. This is called the population attributable risk percent (PAR%), also 
known as the etiologic factor that describes what percent of the disease would 
be removed if that exposure was removed. For example, 12% of active TB 
disease incidence is attributable to HIV infection, thus if HIV infection was no 
longer a comorbidity with Mtb infection, there would be 12% fewer cases of 
active TB disease worldwide. Although these calculations are rough and 
fraught with assumptions, the question at hand is determining the full suite of 
etiological factors explain LTBI and active TB disease incidence.  
 
Several of these factors link back to the sociological and historical 
understanding of TB. These include malnutrition and air pollution, each of 
which make up around one quarter of risk. Additionally, metabolic syndrome, 
alcohol use, and smoking, all increase risk for active TB disease significantly. 
Nevertheless, is it suspected that these factors are collectively unable to 
explain the full PAR% for why people get active TB, and even fewer factors 
explain why individuals are LTBI. This lack of understanding of the 
epidemiology of TB, in conjunction with the complete lack of understanding as 
to how the microbiome relates to LTBI and active TB disease, is the motivation 
for the study herein.   
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The Human Microbiome 
Microbes and smaller organisms have co-evolved with more complex cellular 
life for the past 500 million years, thus it is not surprising that complex human 
immune systems are adapted to not only recognize and fight off these 
organisms when they are out of check, but to also take advantage of the host 
of biochemical and metabolic functions they possess. For every human cell, 
there is at least one other cell belonging to the microbes that inhabit our 
bodies. These microbes on nearly every exposed surface of the human body 
play an important role throughout the lifecycle of that organism they inhabit—
collectively they are referred to as the microbiota. Most microbes that humans 
are exposed to are non-pathogenic, a relationship called commensalism. 
Many of these microbes actually benefit us, a relationship called mutualism. 
The microbiota help humans to digest food, they biosynthesize small 
molecules like serotonin that regulate our emotions, and teach the immune 
system how to respond to pathogens. The collection of the microorganisms, as 
well as the elaborate biochemical functionality in their genes is referred to as 
the microbiome. These indispensable functions have only been realized 
recently, since the mid 2000s. With the advent of next-generation DNA 
sequencing, culture-independent means to ask which organisms are present, 
and what they are doing, became a reality.  
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Barrier surfaces and the microbiome 
Host-microbe interactions are complex, but one significant feature is that they 
generally involve the interaction of putative pathogens with mucosal barrier 
surfaces. This interaction establishes what sort of biochemical and 
immunological dialogue exists between at the onset of infection or disease, 
thus, understanding the immune status of mucosal surfaces before such an 
event is requisite to understanding these multifaceted host-pathogen 
interactions. Much of the work aimed at understanding these interactions 
involves the study of local microbiome composition at the site of contact.  
 
Increasing evidence clearly demonstrates that these host-pathogen 
exchanges happen frequently and are immunologically important. For 
example, at the largest site of exposure of the immune system to the outside 
world—the gut—it has been shown that temporary infections can permanently 
alter the memory T cell repertoire (4). At baseline regulatory mechanisms exist 
to promote local immune homeostasis, especially involving the anti-
inflammatory properties of intestinal macrophages and at least four unique 
subsets of intestinal dendritic cells (5). A population of innate CD11b+ CD103+ 
dendritic cells in the lamina proproia (LP) constantly surveil the luminal 
contents of the gut—they have mechanisms to transverse the tight junctions of 
the epithelium, sample antigens (including whole bacteria), and bring them 
back to the LP for processing and presentation to B and T cells. Additionally, 
CD11b+ Notch-2 dependent dendritic cells sense bacterial antigens. One 
outcome of this is TLR5 activation by the bacterial protein flagellin, resulting in 
IL-23 production. IL-23 binds to IL-23R receptors on innate lymphoid cells 
(ILCs), which result in the production of IL-22. Most epithelial cells express the 
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IL-22R receptor, and when activated, Il-22R causes antimicrobial peptide 
RegIIIβ and RegIIIγ  production, mucous generation, and the promotion of 
overall intestinal barrier integrity. Additionally, CD4+ lymphoid tissue inducer 
(LTi) cells are rich sources of IL-22 in the gut (6). The importance of IL-22 in 
the context of intestinal homeostasis is highlighted by the collection of 
literature on the negative outcomes of Citrobacter rodentium infection in IL-22-
/- mice, which models human enteropathogenic Escherichia coli infections (7, 
8). This complex series of interactions are complex, and sometimes 
contradictory, given that in some contexts IL-22 can also promote 
inflammation (9). The cocktail of small molecules, chemokines, and cytokines, 
as well as the baseline host-commensal relationship are all factors to consider 
in host-commensal interactions.  
 
Mucosal interactions with the adaptive arm of the immune system often rely on 
antigen-specific cues from the commensal microbiota. In the skin, 
mechanisms exist for establishing local immune homeostasis in conjunction 
with the microbiota. During early life, microbiota of the skin elicit antigen-
specific T cells, and concomitantly establish tolerance by promoting the 
expansion of a population of activated T regulatory cells (Tregs) (10). If Tregs 
are prevented from entering neonatal skin, tolerance to commensals is 
attenuated. In the gut, bacterial antigens are presented to Notch-2-dependent 
dendritic cells (11) that then produce TGFb. Tregs to inhibit effector 
responses, again promoting immune homeostasis in an antigen-dependent 
fashion (12). Collectively, immune tone is determined both locally and 
systemically through the interaction of the microbiota with the host. This 
immune tone is an increasingly important consideration in several contexts 
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and for a number of reasons, and may contribute to the pathogenesis of 
infectious disease.  
 
The long-term response to a pathogen can be controlled spatially, as a 
function of which barrier surface that pathogen invades and what immune cell 
types respond to this invasion. For example, the dimorphic fungus and skin 
commensal organism Candida albicans can gain the ability to transvers the 
skin barrier surface and elicit an immune response. Skin dendritic cells called 
Langerhans cells use Dectin-1 to sense the yeast form of the organism during 
initial breaching of the skin barrier. These cells migrate to lymph nodes and 
produce IL-6, biasing naïve CD4+ cells to adopt a Th17 phenotype. Upon re-
challenge of C. albicans on the skin, but not systemically, mice who have 
undergone this immune challenge are able to resist infection. A different 
population of CD103+ dermal dendritic cells that reside much deeper within 
the barrier surface use TLR2 to sense the filamentous (hyphae) form of C. 
albicans. Migration of these cells to the lymph nodes and production of IL-12 
biases CD4+ naïve cells to the IFNg producing Th1 phenotype. Upon re-
challenge of C. albicans systemically, but not on the skin, mice who have 
undergone this immune challenge can resist infection. Thus, the same 
immune cell type located in two different locations and expressing two different 
receptors results in two different immune tones that can act either locally or at 
a distance.  
 
The repertoire of immune cells at any barrier site and the receptors that they 
express are a function, in part, of the commensal microbiome. In the previous 
example, production of SCFAs by commensal anaerobic bacteria stimulate 
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colonization resistance and inhibit C. albicans growth. Additionally, SCFAs 
induce host immune response factors HIF-1a, a transcription factor involved in 
innate immunity, and the antimicrobial peptide LL-37 (13). For a pathogen, the 
establishment of a replicative niche depends on access to space, nutritional 
factors, and the ability to compete for these within the larger context of an 
ecological community that is the microbiome and the immune responses 
elicited by the host, primarily shaped by the local and distal microbiome.   
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The Microbiome and Tuberculosis  
As discussed, one emerging biological factor that remains unstudied in the 
context of TB susceptibility and treatment is the intestinal microbiota. The 
organisms comprising the intestinal microbiota account for the largest 
exposure of the immune system to the environment, and in turn, the 
composition and metabolic activities of the intestinal bacterial community 
directly participate in the development and function of peripheral immunity 
(14). 
 
Researchers recently described how SCFAs produced by members of the lung 
microbiota can induce peripheral immune phenotypes, leading to increased TB 
susceptibility in HIV+ individuals on antiretroviral therapy (15). In South Africa, 
where the TB epidemic is one of the most severe in the world, researchers 
recruited individuals in a longitudinal clinical study, and investigated both the 
composition of the lung microbiota, as well as the microbe-derived small 
molecules present in the periphery. Predictors of TB hazard include serum 
IFNg IL-17A, butyrate, and propionate, which related to Treg expansion and 
likely attenuation of a productive pro-inflammatory immune response against 
Mtb upon initial infection or reactivation. 
 
It is unknown how the composition of the gut microbiome affects TB, nor is it 
easy to predict. Even small changes in low abundance bacteria of the 
intestinal microbiota can have large effects on health outcomes. For example, 
the mucin-degrading species Akkermansia muciniphila comprises only 1 – 3% 
of the intestinal microbiota of some people, but its loss is associated with 
obesity, Type 2 diabetes, and inflammation in both mice and humans (16-18). 
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Similarly, babies with depletion of four microbiota constituents are at risk for 
asthma, and transfer of these four bacteria to germ free mice ameliorates Th2-
mediated airway inflammation (19).  
 
Although intestinal microbiome composition can be determined by many 
factors throughout a lifetime, there is an increasingly well-understood stability 
in its composition (20) in the absence of antibiotic perturbation. The human 
intestinal microbiome taxonomic composition is dominated by Firmicutes and 
Bacteroidetes, somewhat lower levels of Actinobacteria and Proteobacteria, 
and often low abundance but important phyla like Verrucomicrobia, 
Fusobacteria, and Euryarchaeota (21). Antibiotics can target any of these 
taxa, and have distinctive microbiome-altering effects both during and post 
treatment. For example, the fluoroquinolone ciprofloxacin has broad effects on 
intestinal microbiota, especially Enterobactericeae (22), and causes a marked 
decrease in taxonomic diversity (23). b-lactam antibiotics also cause 
detectable microbiomic shifts, resulting in altered carbohydrate processing and 
increased sugar metabolism (24). Antibiotic induced perturbations of the 
intestinal microbiome can also result in altered metabolite production by the 
microbiota. The third-generation cephalosporin cefoperazone, when 
administered to mice for 10 days, increased secondary bile acid, glucose, free 
fatty acids, and dipeptide production, while decreasing primary bile acids and 
sugar alcohols in the intestine (25). In people undergoing cancer treatment, 
treatment with metronidazole led to substantial derangement of the microbiota 
through its anti-anaerobic activity; in contrast, treatment with intravenous 
vancomycin had relatively little impact (26). Although the pre-treatment 
ecological state of the microbiome generally recovers after stopping antibiotic 
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treatment, there are noticeable effects that may persist for weeks, months, and 
even years after treatment is stopped (27). Although these are just a few 
examples, the current model is that antibiotic treatment can result in the 
establishment of an alternative state that can have systemic, often deleterious, 
consequences for immunity and disease susceptibility (21, 28).  
Motivation for Study 
Little is known about the effects of first-line TB antibiotics on the intestinal 
microbiome. In contrast to commonly used broad spectrum antimicrobials, 
most first-line antibiotics used to treat TB are narrow spectrum agents with 
Mycobacteria-specific targets. A standard course of TB therapy for drug 
sensitive Mtb consists of the administration of four drugs for two months, 
Isoniazid (H), Rifampin (R), Pyrazinamide (Z), Ethambutol (E), and then the 
continuation of HR for an additional four months. Isoniazid is a prodrug, which 
requires the mycobacterial catalase-peroxidase KatG (Rv1908c) for ligation 
with NAD+, the product of which is the active drug that inhibits enoyl-acyl 
carrier protein reductase InhA, thereby inhibiting mycolic acid biosynthesis 
(Figure 1) (29). Similarly, pyrazinamide is only used clinically for Mtb and is 
converted to the active pyrazinoic acid by the bacterial amidase PncA (Figure 
1) (30). Ethambutol is thought to inhibit arabinosyltransferases, and like 
isoniazid, inhibit cell wall biosynthesis. Of the four standard TB antibiotics used 
in “short course” treatment (HRZE), only Rifampin, which inhibits bacterial 
RNA polymerase, is a broad-spectrum antimicrobial that is used for non-
mycobacterial infections. The effects of this prolonged antibiotic regimen on 
the intestinal microbiota are unknown, and almost impossible to predict.  
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In this study, we characterize for the first time the intestinal microbiome of 
residents of Haiti and assess the immediate and long-term effects of TB 
treatment with HRZE antimycobacterial therapy on microbial diversity, 
taxonomic composition, and biochemical capacity. We demonstrate the 
substantial and unique disruptive effects of HRZE therapy on intestinal 
microbiome composition using both 16S and metagenomic DNA sequencing 
and demonstrate that long term gut microbiomic dysbiosis is a consequence of 
TB treatment.   
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CHAPTER 2 – RESULTS 
Clinical characteristics of study groups from the TBRU study 
We recruited four groups of individuals using a cross-sectional research study 
design. To characterize the intestinal microbiomes of individuals from the 
Haitian population, we recruited two groups of control individuals, 50 with no 
Mtb infection, and 25 latently infected by Mtb (LTBI), as defined by a positive 
Interferon Gamma Release Assay (IGRA) test. To determine the effect of 
HRZE antimycobacterial treatment on the intestinal microbiome, we recruited 
19 volunteers currently on treatment with HRZE for drug sensitive 
Tuberculosis. In addition, to determine the duration of the microbiome 
perturbation of HRZE treatment, we recruited 14 previously treated cases who 
were cured of active TB. The clinical characteristics of the groups are given in 
Table 1. To appropriately control for age, we divided our LTBI group into two 
distinct control subgroups, designated LTBI (treatment control) and LTBI 
(cured control), since microbiome composition can vary significantly with age 
(31).  
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Table 1: Patient populations analyzed in this study for 16S rDNA sequencing. Data are 
divided into study groups described in the text. The number of participants, participants average 
age, gender distribution, amount of time on HRZE treatment or time since treatment, average 
number of 16S reads and subsequent OTUs, and Shannon diversity index are shown if 
applicable.  
  
Group 
Number 
of 
people 
Average 
Age 
(range) 
% 
female 
Time on 
TB 
treatment 
Time 
since TB 
treatment 
Average 
number 
of 16S 
reads 
per 
patient 
(range) 
Average 
number 
of OTUs 
per 
subject 
(range) 
Shannon 
Diversity 
Healthy 
control  50 
33 (19 – 
59) 62 N/A N/A 
35951 
(690 – 
116638) 
230 (19 
– 473) 3.412 
LTBI 
(treatment 
control) 
25 26 (17 – 32) 52 N/A N/A 
41038 
(4713 – 
118110) 
229 (47 
– 470) 3.341 
LTBI (cured 
control) 17 
24 (17 – 
29) 50 N/A N/A 
48329 
(8309 – 
118110) 
247 (119 
– 453) 3.417 
Treatment 19 20 (13 – 32) 54 
3.2 
months 
(13 – 217 
days) 
N/A 
38489 
(4360 – 
140543) 
150 (57 
– 118) 3.218 
Cured 14 23 (17 – 27) 36 6 months 
417 days 
(34 – 
1202 
days) 
21731 
(5134 – 
105583) 
237 (142 
– 388) 3.75 
Human 
Microbiome 
Project 
(Americans) 
319 N/A 57 N/A N/A 
15937 
(114 –  
53607) 
58 (17 – 
139) 2.347 
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Characterization of the healthy Haitian intestinal microbiome  
Today, Haiti is the most financially impoverished country in the Western 
Hemisphere, with more than 80% of the population living below the poverty 
line. This cycle of poverty was recently amplified by a massive earthquake in 
2010 that killed 300,000 people and displaced more than 1.5 million people. 
The socioeconomic reality of Haiti contributes to a TB epidemic that affects the 
entire population; the incidence of active TB in Haiti is 194 per 100,000 people 
(1).  
 
Most microbiome studies in humans have been performed on relatively 
affluent populations in North America or Europe, with a relative paucity of 
large-scale studies in developing nations. Given the substantial effect of diet 
and other factors on microbiome composition, and the lack of data about 
microbiome composition in TB endemic countries, we initially characterized 
the healthy Haitian adult microbiome by enrolling 50 Mtb-uninfected, 
apparently healthy, Haitian individuals with no known recent Mtb exposure, 
and collected stool for 16S rDNA and metagenomic DNA sequencing. The 
mean age for volunteers in the healthy group was 33 years old (range 19 – 59 
years), with 62% who were female. To our knowledge, this is the first 
characterization of the intestinal microbiome from Haitians.  
 
Microbiome composition was first characterized through sequencing of the 
V4–V5 variable region of the 16S ribosomal DNA gene. Reads were filtered for 
size and quality and chimeras were removed to yield an average of 35,951 
high-quality reads per patient (Table 1). Reads were clustered into operational 
taxonomic units (OTUs) at 97% identity, and taxonomic identification was 
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made using BLASTn against the refseq_rna database (32). We also analyzed 
both 16S (319 subjects) and metagenomic data (150 subjects) from healthy 
individuals recruited from the American Human Microbiome Project (HMP) (33, 
34). Using metagenomic data, we found a statistically significant different 
mean Shannon diversity index between the HMP and Haitian populations 
(Wilcoxon rank sum test with continuity correction, p=0.0131), indicating that 
the Haitian microbiome is more diverse than the American counterpart (Figure 
3). Non-metric multidimensional scaling (NMDS) principal component analysis 
on Bray Curtis distances clearly separated HMP samples from either Mtb 
uninfected Haitian samples or Haitian LTBI samples (Figure 4A). 
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Figure 3: Shannon diversity index for the Haitian and Human Microbiome Project samples. 
Calculated using metagenomic data and the Vegan package in R (35). Unique species are 
acting as the input for each person. The Haitian vs HMP cohorts have statistically significant 
different Shannon diversity indices (p=0.0127).  
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To obtain species level resolution of the differences between the two 
populations, we performed taxonomic profiling of the metagenomes from the 
150 healthy HMP individuals (see above) and from 43 healthy Haitian 
individuals (No TB: 18 + LTBI: 25) using the Metaphlan pipeline (36). The 
most abundant taxonomic genera in the healthy Haitian group come from 
Prevotella, Faecalibacterium, Ruminococcus, Bacteroides, Oscillibacter, 
Blautia, Bifidobacterium, Agathobacter, Romboutsia, Gemmiger, Coprococcus, 
Holdemanella, Lactobacillus, Eubacterium, Anaerostipes, Sporobacter, 
Clostridium, Catenibacterium, and Akkermansia (Figure 4). The most 
abundant genus is Prevotella, from the Phylum Bacteroidetes. The 
preponderance of Prevotella is similar to prior characterization of microbiome 
composition in other non-Western populations (37, 38).  
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Figure 4: Characterization of the healthy Haitian microbiome in comparison to the Human 
Microbiome Project by 16S and metagenomic DNA sequencing. A. NMDS plot on Bray 
Curtis distances between healthy Haitian (both LTBI (red) and Mtb uninfected (blue) and HMP 
samples (green), based on metagenomic DNA sequencing, highlighting differences between 
the two populations and the lack of difference between LTBI and No TB subjects. B. The 40 
most abundant taxa in both Haitian and HMP samples using metagenomic sequencing. C. 
Unsupervised hierarchical clustering of the 40 most abundant taxa of the 319 intestinal 
microbiome samples from the American Human Microbiome Project determined by 16S rDNA 
sequencing. D. Unsupervised hierarchical clustering the 40 most abundant taxa from 50 Mtb 
uninfected Haitian subjects using 16S rDNA sequencing. 
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Figure 5: Differentially abundant taxa between Haitian and HMP samples. LEfSe was used 
to determine the major differences in taxonomy using Metaphlan taxonomic assignments on 
metagenomic data, and the relative abundance of the most significantly different taxa are 
plotted. Phylum, Class, Genus, and Species level comparisons are plotted between 150 HMP 
metagenomic samples with 42 healthy (No TB + LTBI) Haitian individuals. All biomarkers are 
derived from a Wilcoxon Rank Sum test p < 0.01 and have an linear discriminant analysis effect 
size score > 4.2. The median of the data in the box is indicated by a line, the whiskers show 1.5 
times the value of the interquartile range of the box hinge, and outliers are shown separately as 
dots. 
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Hierarchical clustering of the top 40 most abundant OTUs for each group 
determined by 16S sequencing highlighted the heterogeneity of microbiome 
composition among healthy individuals within a population (Figure 4C and 4D). 
Comparison between Haitian and American data showed that despite being 
the dominant Phyla in both populations, Firmicutes were more abundant in the 
Haitian population (77.9% vs 64.8%), whereas Bacteroidetes were more 
abundant in the American population (21.4% vs 10.8%, Table S1, Figure 4). 
Two additional Phyla were found to have increased abundance in the Haitian 
population, Actinobacteria, the Phylum to which Mtb belongs, and 
Euryarchaeota (Archaeal Kingdom), whereas Proteobacteria and Spirochetes 
did not significantly differ between the two populations. Using LEfSe (39) to 
compare the most differentially abundant species between the two 
populations, we determined that on average Haitians have higher levels of 
Bifidobacterium, Blautia, Catenibacterium, Collinsella, Coprococcus, 
Erysipelotrichaceae, Eubacterium, Faecalibacterium, Lactobacillus, 
Methanobrevibacter, Mitsuokella, Olsenella, Peptostreptococcaceae, 
Prevotella, Rothia, and Streptococcus. By contrast, Americans have higher 
levels of Adlercreutzia, Alistipes, Bacteroides, Burkholderiales, Holdemania, 
Parabacteroides, and Parasutterella (Figure 4). We recognize that 16S data 
obtained from the HMP will differ with respect to DNA extraction, library 
preparation, and DNA sequencing. We downloaded the HMP dataset and 
performed OTU calling using our protocol and nomenclature (i.e., OTU names 
were called from the refseq_rna database), and at this level of comparison, we 
believe these OTUs accurately differ between the two populations.   
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Figure 6: Metacyc pathway abundance comparing the HMP dataset and Haitian healthy 
control people. A. Unsuprivised hiericherical clustering of significantly altered Metacyc 
pathways. B. Relative abundnace of Metacyc pathways, significant by LeFSe (p< 0.01). 
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Figure 7: Metacyc pathway coverage comparing the HMP dataset and Haitian healthy 
control people. A. Unsuprivised hiericherical clustering of significantly altered Metacyc 
pathway coverage. B. Relative abundnace of Metacyc pathway coverage, significant by 
LeFSe (p< 0.01).  
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Figure 8: KEGG pathways comparing the HMP dataset and Haitian healthy control 
people. A. Unsuprivised hiericherical clustering of significantly altered KEGG pathways. B. 
Relative abundnace of KEGG pathways, significant by LeFSe (p< 0.01). 
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Figure 9: Metacyc pathway coverage comparing the HMP dataset and Haitian healthy 
control people. A. Unsuprivised hiericherical clustering of significantly altered Metacyc 
pathway coverage. B. Relative abundnace of Metacyc pathway coverage, significant by 
LeFSe (p< 0.01).  
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To determine whether the observed taxonomic compositional differences 
between Haitians and HMP samples are reflected in distinct functional 
differences (i.e., coding capacity) we mapped the abundances of 
Uniref/Metacyc pathway abundance and coverage, as well as KEGG 
pathways and modules using the HUMAnN2 software pipeline (40). Principal  
component analysis on pathway differences sharply distinguishes the Haitian 
and American groups, regardless of their Mtb infection status (not shown), so 
we further investigated these differences using differential statistics (see 
Methods). Comparison of the HMP and Haitian groups resulted in many 
pathway differences that were either enriched or reduced in each population, 
regardless of which statistical method was used to delineate group functional 
differences (Figures S4 – S7). Additionally, unsupervised hierarchical 
clustering of samples successfully delineates HMP samples from Haitian 
samples (Figures 6 – 9). These pathways broadly encompass multiple aspects 
of bacterial central metabolism and cofactor biosynthesis (see SI text for 
details), further emphasizing the significant differences between Haitian and 
American microbiome composition. Taken together, this analysis suggests that 
the two populations differ not only in terms of microbial composition but also in 
biochemical functionality.  
 
In summary, we present the first taxonomic characterization of the intestinal 
microbiome from the Haitian population. The Haitian microbiome differs 
substantially from that of the United States samples included in the original 
Human Microbiome Project, and our data therefore augments a sparse 
literature on microbiome composition in people from both developing and TB 
endemic countries and regions. The most prominent differences in 
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microbiomic configuration are the abundance of Prevotella, Bifidobacterium, 
and Ruminococcus in the Haitian microbiome. The Haitian intestinal 
microbiome contains a high abundance of Prevotella, known to degrade xylan 
and other starches from dietary fiber, (41) and also observed in high 
abundance in other “non-Western” or African populations (31, 42, 43). 
Additionally, we found overlap in the differences in coding capacity between 
populations from developing and developed countries, which are similar to 
previous findings. One report in particular compares people recruited from the 
USA, native people from the Amazonas of Venezuela, and residents of rural 
Malawian communities (31). In the USA samples, compared to those of the 
people from Venezuela and Malawi, researchers found an increase in sugar 
(glycan) degradation, lipoic acid metabolism, and bile salt degradation. This 
result is strikingly similar to the findings presented here comparing HMP 
samples to healthy Haitians. Additionally, metagenomic studies on the Hadza 
hunter-gathers in Africa shows similarities with the Haitian data as well (42).  
 
Pathway differences between HMP and Haitian microbiomes 
In the HMP samples, several of the pathways that are differentially abundant 
generally relate to metabolism. For example, a variety of metabolic pathways 
including those for lipoic acid, glycan degradation, secondary bile acid 
synthesis, synthesis of LPS, and secondary polyketide synthesis are more 
abundant (Figures 6 – 9). Lipoic acid plays a role in lysine biosynthesis and 
metabolism (also enriched in HMP samples, PWY 2942), which is important 
for the regulation of energy production via the pyruvate dehydrogenase 
complex (44). Sugar biosynthesis and degradation, including that for 
glycosaminoglycan (ko00531) and fructose and mannose (ko00051), 
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rhamnose (DTDPRHAMSYN PWAY and RHAMCAT PWY), and galactose 
(PWY 6317 and PWY66 422) are significantly enriched in HMP samples, a 
finding recapitulated from the original HMP data, and possibly is a result of the 
American diet of the sampled individuals (45). Secondary bile acids, enriched 
in the HMP samples (ko00121), have been studied extensively and have both 
positive and negative health effects, including conferring resistance to 
colonization by C. difficile (46). Finally, secondary polyketide synthesis, 
specifically of antibiotics like streptomycin (ko00521), were more prevalent in 
the HMP samples. Synthesis of these molecules results in competition 
between susceptible and insensitive bacteria in the gut microbiome milieu.  
 
Distinct functional pathways were enriched in the Haitian samples. Two 
pathways in particular, bacterial chemotaxis (ko02030) and flagellar assembly 
(ko02040) both related to mobility of bacteria and have been implicated in 
inflammation (47). Several pathways involved in amino acid biosynthesis 
including alanine (ko00473), valine, leucine, and isoleucine (ko00290), 
cysteine and methionine (ko00270), lysine (ko00300), methionine (HOMOSER 
METSYN PWY), aromatic amino acids (COMPLETE ARO PWY), and taurine 
and hypotaurine (ko00430). Finally, several enzymatic cofactors like S-
adenosyl methionine utilization and recycling (PWY 6151), and chorismate 
biosynthesis (PWY 6163) are overrepresented in the Haitian samples (Figures 
6 – 9).  
 
Taken together, these results indicate that functional pathway differences 
between Haitian and HMP samples are significant, and recapitulate previous 
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findings where populations with non-Western diets and lifestyles were 
compared to those with them (31, 37, 42).  
 
Antimycobacterial treatment alters intestinal microbiota taxonomic 
composition during treatment without affecting overall diversity 
It is currently unknown if and how the standard regimen of antimycobacterial 
HRZE therapy affects the taxonomic composition of the intestinal microbiota, 
as none of these drugs have been studied, alone or in combination, for their 
effects in humans. We used a cross-sectional enrollment design to determine 
if and how the intestinal microbiota changes in response to HRZE therapy in 
people from Haiti. All cases were recruited from the Haitian community, had 
recently been diagnosed with microbiologically-confirmed M. tuberculosis 
infection, and have been on a combination regimen of HRZE antibiotics for at 
least two weeks (Treatment group, Table 1). We compared Mtb uninfected 
and LTBI controls with no known recent or historical Mtb exposure. Using 
either a DESeq or LeFSe analytical pipeline (see Methods), we were unable to 
detect any microbiomic differences between Mtb uninfected and LTBI 
individuals (data not shown), and quantitative Permanova analysis further 
confirm this finding (Table 2, see Methods). Thus, we conclude that LTBI has 
no detectable effect on intestinal microbiome composition.  
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Figure 10: HRZE treatment perturbs the taxonomic structure of the microbiome. A. NMDS 
ordination of HRZE treated subjects (purple) or LTBI controls (blue) based on 16S rDNA 
sequencing B. Family taxonomic distribution of the intestinal microbiota from subjects with LTBI 
and subjects with TB on treatment. C. Heatmap of the top 50 most abundant taxa generated 
with DESeq2 showing unsupervised clustering of TB cases on treatment vs. LTBI controls. Age 
and sex are also shown but were not accounted for the in DESeq model. D. Taxonomic 
abundance profiling comparing treatment vs LTBI participants using LeFSe to determine 
differentially abundant Genera. Box and whisker plots of differentially abundant genera are 
shown based on the DESeq normalized data. Plots show the first and third quartiles of the 
abundance data, the line represents the median, and the whiskers show 1.5 times the value of 
the interquartile range. Outliers are shown as dots.  
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In comparing individuals on HRZE treatment with LTBI controls, we were 
surprised to find that overall microbiomic diversity of volunteers treated for 
active TB with HRZE did not differ from controls, as measured by the Shannon 
diversity index, despite being on therapy for an average of 3.2 months (Figure 
11B, Table 1). This lack of effect on diversity is in stark contrast to the 
dramatic and rapid loss of diversity seen with broadly acting antimicrobials 
(48), and is consistent with the narrower spectrum of antimycobacterial agents 
used for treatment of TB. We additionally compared the Treatment group to 
the Mtb uninfected controls, and found similar differences (data not shown). 
Nevertheless, there was a highly significant loss of specific taxa of bacteria 
with antimycobacterial treatment (i.e., the number of unique OTUs). The 
number of observed OTUs was significantly lower in the treatment group 
compared to the Mtb uninfected (two-samples t-test; p = 0.0074) or LTBI-
treatment (two-samples t-test; p = 0.0122) control groups (Figure 11C). 
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Figure 11: Taxonomic richness and diversity in Haitian cohorts used in this study. A. 
Shannon diversity index measured for all groups used in this study, based on 16S rDNA 
sequencing data. The LTBI (treatment) group indicates subjects who are the age-matched 
controls for the treatment group, and the LTBI (cured) group indicates the age-matched controls 
for the cured group. B. Raw number of observed OTUs clustered at 97% similarity for the clinical 
groups in this study.  
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Despite the lack of an effect on overall diversity, closer examination of specific 
microbiomic changes associated with treatment revealed substantial changes 
in the treated group compared to either the Mtb uninfected control group or 
LTBI controls. Principal  coordinate analysis on differential taxonomic diversity 
calculated either using 16S (Figure 10A, HRZE vs LTBI) or metagenomic DNA 
sequencing (Figure 12A, HRZE vs healthy) clearly demarcates people who are 
on treatment from those who are not, indicating substantial antimycobacterial-
induced perturbations. A quantitative test of what variables account for 
variance between two groups (Permanova) confirms differences between the 
treatment and healthy groups (p=0.023, Table 2, see Methods). We were 
unable to find differences based on sex of the individual (p=0.44, Table 2), 
which we accounted for due to the unbalanced gender distribution of the 
groups, and in all analyses performed, treatment contributed the largest to the 
observed variance (Table 2). Unsupervised hierarchical clustering of the 40 
most abundant OTUs revealed similar distinctions between treated and control 
subjects (Figure 10C), and revealed that treated people clustered into two 
major groups. The predominant cluster in the treated group is represented by 
an overabundance of Prevotella copri and P. denticola (as representative 
organisms), and the other by its depletion (Figure 10C). 
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Treatment vs LTBI 
Unifrac F.Model R2 Pr(>F) 
TB status 3.6433 0.07804 0.001 
age 1.0898 0.02334 0.297 
sex 0.9546 0.02045 0.446 
Bray F.Model R2 Pr(>F) 
TB status 1.93533 0.04266 0.019 
age 1.43693 0.03167 0.086 
sex 0.99648 0.02196 0.414 
Jaccard F.Model R2 Pr(>F) 
TB status 1.63854 0.03652 0.007 
age 1.24754 0.0278 0.098 
sex 0.98374 0.02192 0.457 
No TB vs LTBI (30 in each group, Haitian 
community controls) Unifrac F.Model R2 Pr(>F) 
TB status 0.64947 0.00961 0.924 
age 1.29284 0.01913 0.164 
sex 0.63887 0.00945 0.938 
Bray F.Model R2 Pr(>F) 
TB status 0.75282 0.01099 0.823 
age 1.69801 0.02478 0.035 
sex 1.0744 0.01568 0.296 
Jaccard F.Model R2 Pr(>F) 
TB status 0.8399 0.01229 0.837 
age 1.4459 0.02116 0.029 
sex 1.0342 0.01514 0.337 
Cured vs LTBI 
Unifrac F.Model R2 Pr(>F) 
TB status 1.1042 0.03532 0.272 
age 1.1169 0.03572 0.277 
sex 1.0464 0.03347 0.359 
Bray F.Model R2 Pr(>F) 
TB status 1.89019 0.0587 0.009 
age 1.46281 0.04543 0.042 
sex 0.84962 0.02638 0.671 
Jaccard F.Model R2 Pr(>F) 
TB status 1.5714 0.04957 0.007 
age 1.2373 0.03903 0.085 
sex 0.89447 0.02821 0.725 
Table 2: PERMANOVA test results for the treatment vs LTBI and cured vs LTBI comparisons, 
as well as the comparison between No TB and LTBI cohorts as a control, using three different 
distance metrics (Bray Curtis distances, Jaccard distances, and unweighted Unifrac 
distances). This demonstrates what factors (age, sex, TB status) contribute to the observed 
variation between the cohorts. 
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Figure 12: Taxonomic and biochemical microbiomic perturbation induced by HRZE. A. 
NMDS ordination plot on metagenomic taxonomy data demonstrating microbiomic differences 
between healthy individuals and subjects on HRZE treatment. For this comparison, the healthy 
group consists of LTBI and Mtb uninfected subjects. B. Comparative abundance plots between 
healthy Haitian individuals and cases on HRZE treatment showing the most abundant species. 
C. Unsupervised hiericheral clustering of significantly altered taxa from species-level 
metagenomic data. D. Abundance of significantly different KEGG modules between healthy 
volunteers and cases on treatment. 
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To determine which taxa are significantly affected by HRZE therapy, we used 
both the LEfSe and DESeq2 pipelines with 16S rDNA sequencing data (see 
Methods) and observed dramatic changes at the Genus level. Subjects taking 
HRZE have, on average, an enrichment of Erysipelatoclostridium (8.8% in the 
Treatment group vs. 3.4% in LTBI controls), Fusobacterium (0.08% in the 
Treatment group vs. 0.54% in LTBI controls) and Prevotella (7.11% in the 
Treatment group vs. 3.76% in LTBI controls). HRZE treatment resulted in a 
10-fold reduction in Blautia, a more than a 200-fold reduction in Lactobacillus 
and Coprococcus, and a 675-fold decrease in Ruminococcus compared to the 
LTBI group (Figure 10D). In the Phylum Actinobacteria, there was a nearly 20-
fold depletion of Bifidobacterium (Figure 10D).  
 
Although 16S rDNA based taxonomic analysis provides useful information 
about the relative abundances of microbiome constituents, and clearly HRZE 
treatment induces a profound alteration in the compositional structure of the 
gut microbiome, this technique cannot directly interrogate the coding capacity 
of the microbiota, as the gene content of taxonomically identical OTUs can 
differ substantially. To ask whether HRZE treatment altered metabolic coding 
capacity of the microbiota, we performed metagenomic sequencing and 
analyzed the coding capacity of HRZE treated subjects vs a control group 
consisting of LTBI and TB uninfected subjects (designated healthy in Figure 
12). Taxonomic analysis by LEfSe revealed similar depletion of 
Ruminococcus, Eubacterium, and other species as was observed with 16S 
profiling, and differentially abundant species by LeFSe clustered well in a 
heatmap analysis (Figure 12C). Using the HUMANn2 software pipeline (40) 
we observed both enrichment and depletion of biochemical pathways within 
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the microbiome of treated volunteers, with the most dramatic changes 
including overabundance of fatty acid oxidation and vitamin biosynthesis and 
depletion of conjugated bile acid biosynthesis with HRZE treatment (Figure 
12D, Figure S10-S12). These results further confirm that HRZE treatment 
broadly perturbs the microbiome, both on the taxonomic and functional levels.  
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Figure 13: Metacyc pathway abundance calculated against the UniRef50 gene database 
comparing healthy (uninfected and LTBI) to treated people. A. Top 20 most abundant 
pathways in the healthy and treated groups. B. Unsuprivised hiericherical clustering of 
significantly altered Metacyc pathways. C. Relative abundnace of Metacyc pathways, 
significant by LeFSe (p< 0.05), between healthy and treatment groups using Metacyc pathway 
coverage.  
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Figure 14: KEGG pathways comparing healthy (uninfected and LTBI) to treated people. 
A. Top 20 most abundant pathways in the healthy and treated groups. B. Unsuprivised 
hiericherical clustering of significantly altered KEGG pathways. C. Relative abundnace of 
KEGG pathways, significant by LeFSe (p< 0.05), between healthy and treatment groups using 
KEGG pathways.  
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Figure 15: KEGG modules comparing healthy (uninfected and LTBI) to treated people. 
A. Top 20 most abundant pathways in the healthy and treated groups. B. Unsuprivised 
hiericherical clustering of significantly altered KEGG modules in patients on HRZE treatmnet. 
C. Relative abundnace of KEGG modules between healthy and treatment groups. 
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TB treatment is associated with a lasting intestinal microbiome 
dysbiosis 
Compelling evidence suggests that alterations in intestinal microbiome 
composition through antibiotic perturbation can result in the development of 
novel ecological states with preliminarily characterized, but poorly defined, 
health outcomes (49). The data presented above clearly indicates that HRZE 
treatment induces a detectable microbiomic perturbation, which could be long 
lasting given the prolonged duration of antibiotic exposure during TB 
treatment. To determine whether the dysbiosis induced by antimycobacterials 
persists after discontinuation of therapy, we recruited a group of cured TB 
cases who had completed 6-month HRZE therapy for active Tuberculosis and 
compared their microbiome composition to age matched LTBI subjects as 
controls. The average time since completion of treatment in the cured group 
was 1.2 years (mean 417 days, range 34-1202 days, Table 1). We found that 
taxonomic alpha diversity in the cured subjects remained at levels comparable 
with those in the LTBI control groups (Figure 11B). Indeed, using a Mann-
Whitney unpaired t-test, there is a slight significant increase in Shannon 
diversity for the cured cases (p=0.0336, Figure 11B). However, the intestinal 
microbiomes of cured TB cases were distinguishable from LTBI controls when 
examined by detrended correspondence principal  component analysis (Figure 
16A), indicating that HRZE therapy has long-lasting effects on microbiome 
composition (Figure 16B).  
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Figure 16: TB treatment induces a lasting alteration in microbiome structure. 
A. DCA ordination plot of cured cases compared to LTBI controls B. Family level taxonomic 
distribution of the intestinal microbiota from subjects with LTBI or who are cured. C. Heatmap 
of the 40 most abundant taxa generated with DESeq2 showing unsupervised clustering of cured 
vs. LTBI subjects. Age and sex are also shown but were not accounted for the in DESeq model. 
The number of days that each patient has been off treatment is also shown. D. Taxonomic 
abundance profiling comparing cured vs LTBI subjects. Taxa are significant from LeFSe (p < 
0.05 and LDA cutoff > 3.0).   
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To quantitatively asses the principal  coordinate analysis result, a Permanova 
test was used to confirm differences between the two populations (p=0.046). 
Again, given the uneven distribution of sex in our cohorts, we performed a 
Permanova test on sex, but are unable to detect differences between the 
populations using this measure (p=0.98). Unsupervised hierarchical clustering 
of the 40 most abundant OTUs revealed that in general cured individuals 
clustered away from LTBI controls (Figure 16C). We identified some degree of 
heterogeneity in cured individual’s microbiomes, since there is not perfect 
clustering, but this in no way rules out the presence of altered taxonomic or 
functional microbiomic states. We asked whether this heterogeneity in the 
cured people was correlated with the duration of time since treatment and 
found that both distantly and recently cured people clustered well together, 
indicating that the persistent dysbiosis observed is not simply a marker for 
time since cure (Figure 16C).  
 
We used LeFSe and DESeq to analyze differences between cured individuals 
and LTBI age matched controls. Cured people were depleted in the 
Bacteroidetes Phylum of Bacteroides, Barnesiella, and Blautia (Figure 17D). 
Using metagenomic DNA sequencing and LeFSe, we found that Enterobacter 
cloacae, Phascolarctobacterium succinatutens, Methanobrevibacter smithii, 
Bilophila, and Parabacteroides are biomarkers of cured individuals. Although 
DCA performed with species level abundances on metagenomic data failed to 
cluster healthy and treated cases (Figure 17A), and community structure was 
grossly similar (Figure 17B), pathway abundance analysis revealed that cured 
cases demonstrated altered coding capacity compared to controls. (Figure 
17D and Figures S13 – S15). As with the previous comparison of healthy 
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individuals to cases on HRZE treatment, the perturbed pathways represent 
diverse microbial functions including sugar biosynthesis, protein secretion, and 
central metabolism. We conclude that TB treatment results in long term, and 
perhaps permanent, taxonomic, metagenomic, and biochemical 
consequences via perturbation of the intestinal microbiome. 
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Figure 17: TB treatment induces a lasting alteration in microbiome structure and 
function. A. DCA ordination plot on metagenomic taxonomy data in healthy (Mtb-uninfected 
and LTBI community controls) and cured individuals. B. Comparative abundance plots between 
healthy Haitian individuals and cured subjects showing the top 40 most abundant species 
between the two groups. C. Unsupervised hierarchical clustering of significantly altered taxa. D. 
Abundance of significantly different KEGG modules between healthy and cured subjects.  
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Figure 18: Metacyc pathway abundance calculated against the UniRef50 gene database 
comparing healthy to cured people. A. Top 20 most abundant pathways in the healthy and 
cured groups. B. Unsuprivised hiericherical clustering of significantly altered Metacyc 
pathways. C. Relative abundnace of Metacyc pathways, significant by LeFSe (p< 0.05), 
between healthy and cured groups.  
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Figure 19: KEGG pathways comparing healthy (uninfected and LTBI) to cured people. 
A. KEGG pathways comparing healthy to cured people. A. Top 20 most abundant KEGG 
pathways in the healthy and cured groups. B. Unsuprivised hiericherical clustering of 
significantly altered KEGG pathways. C. Relative abundnace of KEGG pathways, significant 
by LeFSe (p< 0.1), between healthy and cured groups.  
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Figure 20: KEGG modules comparing healthy (uninfected and LTBI) to cured people. A. 
KEGG modules comparing healthy to cured people. A. Top 20 most abundant KEGG modules 
in the healthy and cured groups. B. Unsuprivised hiericherical clustering of significantly altered 
KEGG modules. C. Relative abundnace of KEGG pathways, significant by LeFSe (p< 0.1), 
between healthy and cured groups.  
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Figure 21: Profile of Actinobacteria in the Haitian microbiome. A. Scaled relative 
abundnace of all OTUs from the phylum Actinobacteria from LTBI, treatment, and cured 
individuals shown on a phylogenetic tree layout. B. DESeq variance stabilized transformed 
relative abundances of Actinobacterial OTUs sampled from the intestinal microbiomes of LTBI, 
treatment, and cured individuals.  
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CHAPTER 3 – DISCUSSION 
We present the first characterization of the short and long term effects of 
standard HRZE TB antibiotic treatment on the intestinal microbiome. 
Antibiotics are recognized to perturb the composition of the intestinal 
microbiome, and their use has been associated with potentially deleterious 
consequences (21). This perturbation is best documented for broad spectrum 
antibacterial agents which are active against swaths of bacterial microbiome 
constituents. As such, broad spectrum antimicrobials like the fluoroquinolone 
ciprofloxacin (27) may cause rapid loss of overall diversity and disruption of 
the microbiome’s ability to resist pathogenic colonization, which can 
predispose to disease such as Enterococcus domination and C. difficile 
infection (50). However, treatment of TB employs antimicrobial agents with 
narrower spectrums of activity. Although Rifampin is used for non-
mycobacterial infections, Isoniazid, Pyrazinamide, and Ethambutol are only 
prescribed for TB and are activated by and/or target mycobacterial proteins 
not widely distributed throughout the bacterial Kingdom. Thus, we think it is 
important to understand the potential consequences of HRZE treatment on 
microbiome composition and function in the short and the long term. Since the 
turn on the millennium, 49 million people have been treated with this or similar 
regimens, comprising almost 10 billion doses each drug, making TB treatment 
the most widely administered antibiotic regimen in the world.  
 
Our data indicates that the narrow spectrum of the TB treatment regimen is 
reflected in the preserved overall diversity in HRZE treated cases. However, 
this relatively gross measure of perturbation fails to capture the profound 
effects of HRZE on specific components of the microbiome. Most dramatic is 
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the depletion of multiple species of Ruminococcus, Eubacterium, 
Lactobacillus, and Bacteroides along with a simultaneous increase of 
Erysipeloclostridium and Prevotella. The consequences of this HRZE-induced 
taxonomic perturbation are unknown at present, but several of these bacteria 
have been associated with immune-inducing phenotypes relevant to TB 
immunity. Bacterioides (depleted in treated and cured subjects) 
polysaccharide can modulate host inflammatory responses in mice (51). 
Ruminococcus and Coprococcus are two of the most dramatically depleted 
phyla in HRZE treated patients, and these organisms modulate peripheral 
cytokine production, including IL-1, and IFNg (52). Similarly, Bifidobacterium, 
which we find depleted in HRZE treated cases, can induce a Th17 immune 
response in mice (53). Taken together, these findings suggest that the HRZE-
induced perturbation of the microbiome may have significant effects on 
peripheral immune tone. These potential effects on immunity, coupled with the 
well-documented variability in treatment response to TB, may suggest that 
variability in microbiotic perturbation and peripheral immunity could affect the 
efficacy of TB treatment. The data presented here will now allow for testing of 
this hypothesis using prospectively collected cohorts of TB cases beginning 
treatment, with the aim to correlate their microbiomic disruption with 
microbiologic and immunologic markers of treatment success.  
 
Our findings are also corroborated by a recent study that examined the effect 
of TB treatment in mice (54). During HRZ treatment in mice, a decrease in 
species richness is observed, similar to the significant decrease in the number 
of OTUs during HRZE treatment in humans. In mice, RIF is the major driver of 
taxonomic alteration in the intestinal microbiome, but interestingly, 
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combination therapy gives rise to alterations not found for monotherapy of any 
single antibiotic. Additionally, in both mice and humans there is a significant 
decrease in the number of Clostridia during treatment, including the genera 
Bacteroides, Blautia, Clostridium, and Roseburia.  
 
The other prominent finding from our study is the long-lasting duration of the 
microbiotic disruption induced by HRZE. Our cured group had completed 
treatment on average 1.2 years earlier, yet their microbiomes were still 
detectably different from age matched control subjects. This finding suggests 
that the duration of 6 months of HRZE therapy has long lasting effects on the 
community structure of the microbiome. Furthermore, based on data from 
Namasivayam et al., in both mice and humans there is a persistent 
microbiomic dysbiosis after the completion of HRZ(E) treatment (54). Although 
alpha diversity recovers, taxonomic profiling in mice and humans, and 
functional pathway profiling in humans, suggests that 6-month administration 
of HRZ(E) treatment causes persistent changes. Our study raises the 
possibility that TB therapy permanently changes the ecology of the human 
microbiome.  
 
As is the case for the acute perturbation by HRZE, the consequences of these 
durable changes in cured cases will require further study. It is possible that the 
persistent microbiomic perturbation could predispose to enteric pathogens due 
to loss of colonization resistance. It is also possible that cured individuals 
could be more susceptible to systemic infection due to effects of microbiotic 
alteration and disruption on peripheral immunity. Multiple epidemiological 
studies have indicated that people cured of TB are at higher risk of a second 
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case of TB due to reinfection (55, 56). Although multiple environmental and 
genetic factors likely contribute to this risk, including HIV infection, the findings 
in this study raise the possibility that the persistent microbiomic disruption that 
accompanies curative TB treatment could contribute to post-treatment 
susceptibility to reinfection, perhaps not just with Mtb, but also with other 
diseases associated with an altered immune state.  
 
In summary, we have shown that TB treatment with HRZE in humans perturbs 
the intestinal microbiome in distinct and long lasting ways. Specific genera of 
bacteria are depleted during treatment and functional profiling demonstrates 
altered functional pathway composition. These changes, in terms of both 
taxonomic and metagenomic function, are protracted for more than one year 
after the completion of therapy for TB disease, and are possibly permanent.  
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CHAPTER 4 – METHODS 
DNA extraction from stool 
Stool specimens were collected and stored for less than 24 hours at 4 °C, 
aliquoted (~2 mL each), frozen at -80 °C, and shipped to MSKCC. About 500 
mg of stool from frozen samples was suspended in 500 μl of extraction buffer 
(200 mM Tris-HCl, pH=8.0; 200 mM NaCl; 20 mM EDTA), 210 μl of 20% SDS, 
500 μl of phenol/chloroform/isoamyl alcohol (25:24:1), and 500 μl of 0.1-mm-
diameter zirconia/silica beads (BioSpec Products). Samples were lysed via 
mechanical disruption with a bead beater (BioSpec Products) for two minutes, 
followed by two extractions with phenol/chloroform/isoamyl alcohol (25:24:1). 
DNA was precipitated with ethanol and sodium acetate at -80 °C for 1 hour, 
re-suspended in 200 μl of nuclease-free water, and further purified with the 
QIAamp DNA Mini Kit (Qiagen) according to the manufacturer’s protocols, 
including Protein removal by Proteinase K treatment. DNA was eluted in 200 μl 
of nuclease-free water and sorted at -20 °C.  
 
16S rDNA sequencing  
Primers used to amplify rDNA were: 563F (59-nnnnnnnn-NNNNNNNNNNNN-
AYTGGGYDTAAAGN G-39) and 926R (59-nnnnnnnn-NNNNNNNNNNNN-
CCGTCAATTYHTTTR AGT-39). Each reaction contained 50 ng of purified 
DNA, 0.2 mM dNTPs, 1.5 μM MgCl2, 1.25 U Platinum TaqDNA polymerase, 
2.5 μl of 10 × PCR buffer and 0.2 μM of each primer. A unique 12-base Golay 
barcode (Ns) preceded the primers for sample identification after pooling 
amplicons. One to eight additional nucleotides were added before the barcode 
to offset the sequencing of the primers. Cycling conditions were the following: 
94 °C for 3 min, followed by 27 cycles of 94 °C for 50 s, 51 °C for 30 s and 
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72 °C for 1 min, where the final elongation step was performed at 72 °C for 
5 min. Replicate PCRs were combined and were subsequently purified using 
the Qiaquick PCR Purification Kit (Qiagen) and Qiagen MinElute PCR 
Purification Kit. PCR products were quantified and pooled at equimolar 
amounts before Illumina barcodes and adaptors were ligated on using the 
Illumina TruSeq Sample Preparation procedure. The completed library was 
sequenced on an Ilumina Miseq platform per the Illumina recommended 
protocol.  
 
Bioinformatics Analysis 
For 16S MiSeq sequencing, paired-end reads were joined, demultiplexed, 
filtered for quality using maximum expected error (Emax=1), and dereplicated. 
Sequences were grouped into operational taxonomic units (OTUs) of 97% 
distance-based similarity using UPARSE (57). Potentially chimeric sequences 
were removed using both de novo and reference-based methods (where the 
Gold database was used for the latter) (58). Taxonomic assignments were 
made using BLASTN (59) against the NCBI refseq_rna database with custom 
scripts (32). Our approach allows for the identification of the top 30 taxa 
associated with a particular OTU, thus the taxonomic nomenclature that we 
use for 16S is versatile (data not shown). A biological observation matrix 
(biom) (60) file, a taxonomy file, reference sequence file, and tree file were 
constructed using QIIME commands. These files were imported into R (61) 
and merged with a metadata file into a single Phyloseq object (62). Phyloseq 
was used for all downstream analysis of 16S taxonomic data, and plots were 
made with the ggplot2 package (63). 
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Shotgun Metagenomic Sequencing 
Between 150 and 200 ng of DNA isolated from stool (vide supra) was sheared 
acoustically. Hiseq sequencing libraries were prepared using the KAPA Hyper 
Prep Kit (Roche). PCR amplification of the libraries was carried out for 6 
cycles. Samples were run on a Hiseq 4000 in a 125bp/125bp paired end run, 
using the TruSeq SBS Kit v3 (Illumina). There were an average number of 
read pairs per sample of around 11 million.  
 
Shotgun metagenomics pair-ends reads for corresponding to stool samples 
from 150 individuals (64), were downloaded from the Human Microbiome 
Project Portal at http://www.hmpdacc.org/HMASM/.  
 
For the analysis of shotgun metagenomic reads (i.e. those generated in-
house, characterizing the Haitian group as well as those obtained from the 
HMP portal), sequences were first trimmed and removed of host 
contamination using Trimmomatic (65) and Bowtie2 (66). Host-
decontaminated reads were then profiled for microbial species abundances 
using Metaphlan2 (67), and for abundance of Uniref gene and KEGG 
orthologues, and functional pathways (Metacyc pathways, KEGG pathways, 
and KEGG modules) using the software pipeline HUMAnN2 (40) and in-house 
written scripts (available upon request). Normalized taxonomic, gene, and 
pathway abundances were then used for downstream statistical analysis in R. 
All intestinal microbiome samples were sequenced using 16S rDNA 
sequencing, however, only a subset of controls were sequenced using 
metagenomics. Due to sample size limitations, for the metagenomic DNA 
sequencing comparisons, we combined both uninfected and LTBI individuals 
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into a healthy control group which was used as the comparator for 
metagenomic analyses.  
 
Statistical Analysis  
The ability to detect differentially abundant OTUs between groups of people is 
critical for comparison between groups, and various methods exist and have 
been validated for this sort of analysis. For 16S rDNA sequencing, we 
employed the tools available within the Phyloseq package to manipulate the 
data and metadata for downstream analysis. Raw counts with taxonomy and 
metadata were piped into the DESeq2 package for differential abundance 
analysis using the negative binomial distribution assumption with zero inflation 
(68). This method assumes that for many OTUs, the variance in abundance 
(i.e., read count) between samples or groups exceeds the mean read count 
(often zero). When this is true, the DESeq method can be used to transform 
the data so that between sample or between group differences may be 
compared more accurately. Homoscedastic abundance data was used to 
generate heatmaps in Figures 3C and 3D, by applying a variance stabilizing 
transformation from fitted dispersion-means to transform the count data. We 
additionally employed the microbiome-friendly linear discriminant analysis, 
effect size (LEfSe) tool (39) to detect statistically significant differences 
between clinical groups. This technique first employs the non-parametric 
Kruskal-Wallis (KW) sum-rank test between different groups of people (i.e., 
HMP, healthy [comprised of Mtb uninfected and LTBI], on HRZE treatment, or 
cured), followed by linear discriminant analysis to estimate the size of the 
effect (i.e., the degree of significant differential abundance between a 
particular OTU, taxa, gene, or pathway between groups). We attempted to 
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employ both the DESeq2 and LEfSe methods, and try to emphasize where 
there is overlap. All figures in the paper that are related to 16S sequence 
analysis are plotted using the normalized and transformed abundances from 
the DESeq2 package. For the statistical analysis of the results from shotgun 
metagenomics reads, data were imported into R and converted to Phyloseq 
objects with custom scripts. Custom code implementing non-parametric tests 
(Wilcoxon-signed rank) with FDR correction (Benjamini & Hochberg method) 
as well as LEfSe (39) were used to test for differential abundances for taxa, 
and functional pathways. For the Haitian-HMP LEfSe comparison significance 
for the Kruskall-Wallis test (no subclasses) was assessed at the p-value 
threshold of 0.01. For the LTBI-Treatment and LTBI-Cured comparisons p-
value threshold was kept at 0.05 for both the initial Kruskall-Wallis test and the 
subsequent sex-matched subclasses Wilcoxon-signed rank tests. Shannon 
diversity for the Haitian-HMP comparison was calculated using the Vegan 
package in R based on species number and abundance (35). We additionally 
employed the Permanova and Betadisper tests using the adonis function in 
the Vegan package in R. Adonis partitions a distance matrix of OTU count 
data and runs an analysis of variance between groups of samples. Betadisper 
further supports this conclusion by determining if the variance between the two 
groups is similarly distributed. All box-and-whisker plots were generated with 
the ggplot2 (63) function geom_boxplot, which shows the first and third 
quartiles of the dataset and the median of the data in the box, the whiskers 
show 1.5 times the value of the interquartile range of the box hinge, and 
outliers are shown as dots. All other plots were made using Prism 7.  
 
 
 63 
PncA Coding Capacity Analysis 
To investigate mechanistically how HRZE therapy may be altering the 
microbiome, we reasoned that coding capacity for the gene that is known to 
activate pyrazinamide, PncA, may indicate the degree of perturbation one’s 
microbiome would experience upon HRZE exposure. To search for PncA 
orthologs, we used the Ortholuge Database 
(http://www.pathogenomics.sfu.ca/ortholugedb/), an online resource that is 
able to provide a list of orthologous genes for a given input sequence for both 
Bacteria and Archaea (18). The advantage of using a database like this is that 
it utilizes reciprocal BLAST, which ensures that all of the genes in the output 
are true orthologs of the input gene. Reciprocal BLAST first uses standard 
BLASTp to obtain protein homologs, and then takes the top hit of the BLASTp 
output and re-performs BLAST against the reference genome. Only if the top 
hit of this second step is the input sequence does the program consider the 
two sequences orthologous—a standard generally accepted by biologists (19, 
20). The Ortholuge Database output is a list of protein-coding gene sequences 
of all true orthologs of PncA. We then obtained the nucleotide sequences 
using the NIH command line E-Utilities and E-Direct programs 
(http://www.ncbi.nlm.nih.gov/books/NBK179288/), designed for high-
throughput queries (21). Using a custom BASH script to automatically take the 
ortholog output from the reciprocal BLAST as input into the esearch and efetch 
commands in EDirect, we obtained a fasta file of all protein coding true 
orthologs of PncA.  
 
Next, we used shortBRED to find a unique set of PncA markers to which 
metagenomic reads could be mapped. This software relies on k-mer based 
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identification of protein families from the input PncA sequence. We used 
shortbred_identify.py to cluster the PncA orthologs from all Bacteria and 
Archaea into families and identify k-mers, then used shortbred_quantiy.py to 
map metagenomic reads from the Haitian metagenomic samples to the PncA 
k-mer database.  
 
The output was quantified using Prism 7 and is shown in Figure 22. We were 
unable to detect any statistically significant difference in the coding capacity of 
the microbiomes of relevant cohorts in our study. We thus conclude that 
perturbations induced by pyrazinamide may not be caused directly by the 
canonical active metabolite, pyrazinoic acid (Figure 1).  
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Figure 22: PncA coding capacity for each person calculated from metagenomic data and 
using the ShortBRED program (69). There is no statistically significant difference between any 
cohort’s ability to code for PncA.  
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Patient Recruitment and Protection of Human Subjects  
Subjects were enrolled through the Tri-Intuitional Tuberculosis Research Unit 
(TBRU) in conjunction with the GHESKIO Centers, in Port-au-Prince, Haiti, 
where all participants provided written, informed consent. All TBRU protocols 
and consent forms for samples collected at GHESKIO were approved by 
Institutional Review Boards at the GHESKIO and Weill Cornell Medicine (see 
Study Approval). A dedicated clinical field team at the GHESKIO Centers in 
Port-au-Prince, Haiti recruited research volunteers as part of the NIH U19-
funded Tuberculosis Research Unit (AI111143). Patient Mtb-infection status is 
determined using IFNg release assay (IGRA) status, and active TB disease is 
determined using standard clinical assessments. All cases with active 
pulmonary TB receive periodic follow-up appointments while on treatment, and 
anyone with known contact with an active TB patient receives a six-month 
follow-up and is re-screened for IGRA status. All patient samples were de-
identified on site using a barcode system, before they were shipped to NYC for 
analysis. Human DNA was decontaminated from metagenomic shotgun 
sequencing data before analysis and publication, consistent with the removal 
of all biometric identifiers according the Health Insurance Portability and 
Accountability Act (70). All clinical metadata was collected on site and 
managed through the REDCap data management system (71).  
 
Study Approval 
All volunteers provided written informed consent to participate in this study. All 
protocols and consent forms have been approved by the GHESKIO and Weill 
Cornell Medicine institutional review boards. 
  
 67 
REFERENCES 
1. . World Health Organization; 2016. 
2. Nathan C. What can immunology contribute to the control of the world's 
leading cause of death from bacterial infection? Immunol Rev. 2015;264(1):2-
5. 
3. Abel L, El-Baghdadi J, Bousfiha AA, Casanova JL, and Schurr E. Human 
genetics of tuberculosis: a long and winding road. Philos Trans R Soc Lond B 
Biol Sci. 2014;369(1645):20130428. 
4. Hand TW, Dos Santos LM, Bouladoux N, Molloy MJ, Pagan AJ, Pepper M, 
Maynard CL, Elson CO, 3rd, and Belkaid Y. Acute gastrointestinal infection 
induces long-lived microbiota-specific T cell responses. Science. 
2012;337(6101):1553-6. 
5. Cerovic V, Bain CC, Mowat AM, and Milling SW. Intestinal macrophages and 
dendritic cells: what's the difference? Trends Immunol. 2014;35(6):270-7. 
6. Sonnenberg GF, Monticelli LA, Elloso MM, Fouser LA, and Artis D. CD4(+) 
lymphoid tissue-inducer cells promote innate immunity in the gut. Immunity. 
2011;34(1):122-34. 
7. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, Abbas AR, 
Modrusan Z, Ghilardi N, de Sauvage FJ, et al. Interleukin-22 mediates early 
host defense against attaching and effacing bacterial pathogens. Nat Med. 
2008;14(3):282-9. 
8. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, Wu J, 
and Ouyang W. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced 
dermal inflammation and acanthosis. Nature. 2007;445(7128):648-51. 
9. Song C, Lee JS, Gilfillan S, Robinette ML, Newberry RD, Stappenbeck TS, 
Mack M, Cella M, and Colonna M. Unique and redundant functions of NKp46+ 
ILC3s in models of intestinal inflammation. J Exp Med. 2015;212(11):1869-82. 
10. Scharschmidt TC, Vasquez KS, Truong HA, Gearty SV, Pauli ML, Nosbaum 
A, Gratz IK, Otto M, Moon JJ, Liese J, et al. A Wave of Regulatory T Cells into 
Neonatal Skin Mediates Tolerance to Commensal Microbes. Immunity. 
2015;43(5):1011-21. 
11. Satpathy AT, Briseno CG, Lee JS, Ng D, Manieri NA, Kc W, Wu X, Thomas 
SR, Lee WL, Turkoz M, et al. Notch2-dependent classical dendritic cells 
orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. 
Nat Immunol. 2013;14(9):937-48. 
12. Nutsch K, Chai JN, Ai TL, Russler-Germain E, Feehley T, Nagler CR, and 
Hsieh CS. Rapid and Efficient Generation of Regulatory T Cells to 
Commensal Antigens in the Periphery. Cell Rep. 2016;17(1):206-20. 
13. Fan D, Coughlin LA, Neubauer MM, Kim J, Kim MS, Zhan X, Simms-Waldrip 
TR, Xie Y, Hooper LV, and Koh AY. Activation of HIF-1alpha and LL-37 by 
commensal bacteria inhibits Candida albicans colonization. Nat Med. 
2015;21(7):808-14. 
14. Honda K, and Littman DR. The microbiota in adaptive immune homeostasis 
and disease. Nature. 2016;535(7610):75-84. 
15. Segal LN, Clemente JC, Li Y, Ruan C, Cao J, Danckers M, Morris A, Tapyrik 
S, Wu BG, Diaz P, et al. Anaerobic Bacterial Fermentation Products Increase 
Tuberculosis Risk in Antiretroviral-Drug-Treated HIV Patients. Cell Host 
Microbe. 2017;21(4):530-7 e4. 
 68 
16. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y, 
Derrien M, Muccioli GG, Delzenne NM, et al. Cross-talk between Akkermansia 
muciniphila and intestinal epithelium controls diet-induced obesity. Proc Natl 
Acad Sci U S A. 2013;110(22):9066-71. 
17. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, and Bae JW. An 
increase in the Akkermansia spp. population induced by metformin treatment 
improves glucose homeostasis in diet-induced obese mice. Gut. 
2014;63(5):727-35. 
18. Anhe FF, Roy D, Pilon G, Dudonne S, Matamoros S, Varin TV, Garofalo C, 
Moine Q, Desjardins Y, Levy E, et al. A polyphenol-rich cranberry extract 
protects from diet-induced obesity, insulin resistance and intestinal 
inflammation in association with increased Akkermansia spp. population in the 
gut microbiota of mice. Gut. 2015;64(6):872-83. 
19. Arrieta MC, Stiemsma LT, Dimitriu PA, Thorson L, Russell S, Yurist-Doutsch 
S, Kuzeljevic B, Gold MJ, Britton HM, Lefebvre DL, et al. Early infancy 
microbial and metabolic alterations affect risk of childhood asthma. Sci Transl 
Med. 2015;7(307):307ra152. 
20. Moya A, and Ferrer M. Functional Redundancy-Induced Stability of Gut 
Microbiota Subjected to Disturbance. Trends Microbiol. 2016;24(5):402-13. 
21. Becattini S, Taur Y, and Pamer EG. Antibiotic-Induced Changes in the 
Intestinal Microbiota and Disease. Trends Mol Med. 2016;22(6):458-78. 
22. Brismar B, Edlund C, Malmborg AS, and Nord CE. Ciprofloxacin 
concentrations and impact of the colon microflora in patients undergoing 
colorectal surgery. Antimicrob Agents Chemother. 1990;34(3):481-3. 
23. Dethlefsen L, Huse S, Sogin ML, and Relman DA. The pervasive effects of an 
antibiotic on the human gut microbiota, as revealed by deep 16S rRNA 
sequencing. PLoS Biol. 2008;6(11):e280. 
24. Hernandez E, Bargiela R, Diez MS, Friedrichs A, Perez-Cobas AE, Gosalbes 
MJ, Knecht H, Martinez-Martinez M, Seifert J, von Bergen M, et al. Functional 
consequences of microbial shifts in the human gastrointestinal tract linked to 
antibiotic treatment and obesity. Gut Microbes. 2013;4(4):306-15. 
25. Theriot CM, Koenigsknecht MJ, Carlson PE, Jr., Hatton GE, Nelson AM, Li B, 
Huffnagle GB, J ZL, and Young VB. Antibiotic-induced shifts in the mouse gut 
microbiome and metabolome increase susceptibility to Clostridium difficile 
infection. Nat Commun. 2014;5(3114. 
26. Taur Y, Xavier JB, Lipuma L, Ubeda C, Goldberg J, Gobourne A, Lee YJ, 
Dubin KA, Socci ND, Viale A, et al. Intestinal domination and the risk of 
bacteremia in patients undergoing allogeneic hematopoietic stem cell 
transplantation. Clin Infect Dis. 2012;55(7):905-14. 
27. Dethlefsen L, and Relman DA. Incomplete recovery and individualized 
responses of the human distal gut microbiota to repeated antibiotic 
perturbation. Proc Natl Acad Sci U S A. 2011;108 Suppl 1(4554-61. 
28. Levy M, Kolodziejczyk AA, Thaiss CA, and Elinav E. Dysbiosis and the 
immune system. Nat Rev Immunol. 2017;17(4):219-32. 
29. Rawat R, Whitty A, and Tonge PJ. The isoniazid-NAD adduct is a slow, tight-
binding inhibitor of InhA, the Mycobacterium tuberculosis enoyl reductase: 
adduct affinity and drug resistance. Proc Natl Acad Sci U S A. 
2003;100(24):13881-6. 
 69 
30. Scorpio A, and Zhang Y. Mutations in pncA, a gene encoding 
pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug 
pyrazinamide in tubercle bacillus. Nat Med. 1996;2(6):662-7. 
31. Yatsunenko T, Rey FE, Manary MJ, Trehan I, Dominguez-Bello MG, 
Contreras M, Magris M, Hidalgo G, Baldassano RN, Anokhin AP, et al. Human 
gut microbiome viewed across age and geography. Nature. 
2012;486(7402):222-7. 
32. Geer LY, Marchler-Bauer A, Geer RC, Han L, He J, He S, Liu C, Shi W, and 
Bryant SH. The NCBI BioSystems database. Nucleic Acids Res. 
2010;38(Database issue):D492-6. 
33. Human Microbiome Project C. A framework for human microbiome research. 
Nature. 2012;486(7402):215-21. 
34. Group NHW, Peterson J, Garges S, Giovanni M, McInnes P, Wang L, Schloss 
JA, Bonazzi V, McEwen JE, Wetterstrand KA, et al. The NIH Human 
Microbiome Project. Genome Res. 2009;19(12):2317-23. 
35. Dixon P. VEGAN, a package of R functions for community ecology. J Veg Sci. 
2003;14(6):927-30. 
36. Segata N, Waldron L, Ballarini A, Narasimhan V, Jousson O, and 
Huttenhower C. Metagenomic microbial community profiling using unique 
clade-specific marker genes. Nat Methods. 2012;9(8):811-4. 
37. Schnorr SL, Candela M, Rampelli S, Centanni M, Consolandi C, Basaglia G, 
Turroni S, Biagi E, Peano C, Severgnini M, et al. Gut microbiome of the Hadza 
hunter-gatherers. Nat Commun. 2014;5(3654. 
38. Dehingia M, Devi KT, Talukdar NC, Talukdar R, Reddy N, Mande SS, Deka 
M, and Khan MR. Gut bacterial diversity of the tribes of India and comparison 
with the worldwide data. Sci Rep. 2015;5(18563. 
39. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS, and 
Huttenhower C. Metagenomic biomarker discovery and explanation. Genome 
Biol. 2011;12(6):R60. 
40. Abubucker S, Segata N, Goll J, Schubert AM, Izard J, Cantarel BL, 
Rodriguez-Mueller B, Zucker J, Thiagarajan M, Henrissat B, et al. Metabolic 
reconstruction for metagenomic data and its application to the human 
microbiome. PLoS Comput Biol. 2012;8(6):e1002358. 
41. Flint HJ, Bayer EA, Rincon MT, Lamed R, and White BA. Polysaccharide 
utilization by gut bacteria: potential for new insights from genomic analysis. 
Nat Rev Microbiol. 2008;6(2):121-31. 
42. Rampelli S, Schnorr SL, Consolandi C, Turroni S, Severgnini M, Peano C, 
Brigidi P, Crittenden AN, Henry AG, and Candela M. Metagenome 
Sequencing of the Hadza Hunter-Gatherer Gut Microbiota. Curr Biol. 
2015;25(13):1682-93. 
43. Turroni S, Fiori J, Rampelli S, Schnorr SL, Consolandi C, Barone M, Biagi E, 
Fanelli F, Mezzullo M, Crittenden AN, et al. Fecal metabolome of the Hadza 
hunter-gatherers: a host-microbiome integrative view. Sci Rep. 2016;6(32826. 
44. Goraca A, Huk-Kolega H, Piechota A, Kleniewska P, Ciejka E, and Skibska B. 
Lipoic acid - biological activity and therapeutic potential. Pharmacol Rep. 
2011;63(4):849-58. 
45. Lacombe A, Li RW, Klimis-Zacas D, Kristo AS, Tadepalli S, Krauss E, Young 
R, and Wu VC. Lowbush wild blueberries have the potential to modify gut 
microbiota and xenobiotic metabolism in the rat colon. PLoS One. 
2013;8(6):e67497. 
 70 
46. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu 
H, Kinnebrew M, Viale A, et al. Precision microbiome reconstitution restores 
bile acid mediated resistance to Clostridium difficile. Nature. 
2015;517(7533):205-8. 
47. Anahtar MN, Byrne EH, Doherty KE, Bowman BA, Yamamoto HS, Soumillon 
M, Padavattan N, Ismail N, Moodley A, Sabatini ME, et al. Cervicovaginal 
bacteria are a major modulator of host inflammatory responses in the female 
genital tract. Immunity. 2015;42(5):965-76. 
48. Zaborin A, Smith D, Garfield K, Quensen J, Shakhsheer B, Kade M, Tirrell M, 
Tiedje J, Gilbert JA, Zaborina O, et al. Membership and behavior of ultra-low-
diversity pathogen communities present in the gut of humans during 
prolonged critical illness. MBio. 2014;5(5):e01361-14. 
49. Jernberg C, Lofmark S, Edlund C, and Jansson JK. Long-term ecological 
impacts of antibiotic administration on the human intestinal microbiota. ISME 
J. 2007;1(1):56-66. 
50. Taur Y, and Pamer EG. Harnessing microbiota to kill a pathogen: Fixing the 
microbiota to treat Clostridium difficile infections. Nat Med. 2014;20(3):246-7. 
51. Shen Y, Giardino Torchia ML, Lawson GW, Karp CL, Ashwell JD, and 
Mazmanian SK. Outer membrane vesicles of a human commensal mediate 
immune regulation and disease protection. Cell Host Microbe. 2012;12(4):509-
20. 
52. Schirmer M, Smeekens SP, Vlamakis H, Jaeger M, Oosting M, Franzosa EA, 
Horst RT, Jansen T, Jacobs L, Bonder MJ, et al. Linking the Human Gut 
Microbiome to Inflammatory Cytokine Production Capacity. Cell. 
2016;167(7):1897. 
53. Tan TG, Sefik E, Geva-Zatorsky N, Kua L, Naskar D, Teng F, Pasman L, 
Ortiz-Lopez A, Jupp R, Wu HJ, et al. Identifying species of symbiont bacteria 
from the human gut that, alone, can induce intestinal Th17 cells in mice. Proc 
Natl Acad Sci U S A. 2016;113(50):E8141-E50. 
54. Namasivayam S, Maiga M, Yuan W, Thovarai V, Costa DL, Mittereder LR, 
Wipperman MF, Glickman MS, Dzutsev A, Trinchieri G, et al. Longitudinal 
profiling reveals a persistent intestinal dysbiosis triggered by conventional 
anti-tuberculosis therapy. Microbiome. 2017;5(1):71. 
55. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff 
MW, Enarson DA, Behr MA, and van Helden PD. Rate of reinfection 
tuberculosis after successful treatment is higher than rate of new tuberculosis. 
Am J Respir Crit Care Med. 2005;171(12):1430-5. 
56. Glynn JR, Murray J, Bester A, Nelson G, Shearer S, and Sonnenberg P. High 
rates of recurrence in HIV-infected and HIV-uninfected patients with 
tuberculosis. J Infect Dis. 2010;201(5):704-11. 
57. Edgar RC. UPARSE: highly accurate OTU sequences from microbial amplicon 
reads. Nat Methods. 2013;10(10):996-8. 
58. Haas BJ, Gevers D, Earl AM, Feldgarden M, Ward DV, Giannoukos G, Ciulla 
D, Tabbaa D, Highlander SK, Sodergren E, et al. Chimeric 16S rRNA 
sequence formation and detection in Sanger and 454-pyrosequenced PCR 
amplicons. Genome Res. 2011;21(3):494-504. 
59. Camacho C, Coulouris G, Avagyan V, Ma N, Papadopoulos J, Bealer K, and 
Madden TL. BLAST+: architecture and applications. BMC Bioinformatics. 
2009;10(421. 
 71 
60. McDonald D, Clemente JC, Kuczynski J, Rideout JR, Stombaugh J, Wendel 
D, Wilke A, Huse S, Hufnagle J, Meyer F, et al. The Biological Observation 
Matrix (BIOM) format or: how I learned to stop worrying and love the ome-
ome. Gigascience. 2012;1(1):7. 
61. . R Core Team. Vienna, Austria: R Foundation for Statistical Computing; 2016. 
62. McMurdie PJ, and Holmes S. phyloseq: an R package for reproducible 
interactive analysis and graphics of microbiome census data. PLoS One. 
2013;8(4):e61217. 
63. Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer Publishing 
Company, Incorporated; 2009. 
64. Human Microbiome Project C. Structure, function and diversity of the healthy 
human microbiome. Nature. 2012;486(7402):207-14. 
65. Bolger AM, Lohse M, and Usadel B. Trimmomatic: a flexible trimmer for 
Illumina sequence data. Bioinformatics. 2014;30(15):2114-20. 
66. Langmead B, and Salzberg SL. Fast gapped-read alignment with Bowtie 2. 
Nat Methods. 2012;9(4):357-9. 
67. Truong DT, Franzosa EA, Tickle TL, Scholz M, Weingart G, Pasolli E, Tett A, 
Huttenhower C, and Segata N. MetaPhlAn2 for enhanced metagenomic 
taxonomic profiling. Nat Methods. 2015;12(10):902-3. 
68. Love MI, Huber W, and Anders S. Moderated estimation of fold change and 
dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550. 
69. Kaminski J, Gibson MK, Franzosa EA, Segata N, Dantas G, and Huttenhower 
C. High-Specificity Targeted Functional Profiling in Microbial Communities 
with ShortBRED. PLoS Comput Biol. 2015;11(12):e1004557. 
70. United S. Health Insurance Portability and Accountability Act of 1996. Public 
Law 104-191. US Statut Large. 1996;110(1936-2103. 
71. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, and Conde JG. 
Research electronic data capture (REDCap)--a metadata-driven methodology 
and workflow process for providing translational research informatics support. 
J Biomed Inform. 2009;42(2):377-81. 
 
